期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血管活性药物在肝肾综合征中的应用进展 被引量：2

Progression on the use of vasoactive agents in the treatment of hepatorenal syndrome.
原文传递
导出
摘要 肝肾综合征（hepatorenal syndrome，HRS）是发生在肝硬化腹水患者中一种潜在的可逆眭并发症，也可发生在急性肝功能衰竭或酒精性肝炎患者中。主要特征为肾功能受损，血流动力学明显改变，交感神经和肾素一血管紧张素系统过度活化。
作者 郑颖颖 徐小元
机构地区 北京大学第一医院感染疾病科
出处 《中华肝脏病杂志》 CAS CSCD 北大核心 2011年第9期718-720,共3页 Chinese Journal of Hepatology
基金 国家“十一五”科技重大专项基金（2008ZX10002013）
关键词 肝肾综合征 治疗学 血管收缩药 Hepatorenal syndrome Therapeutics Vasoconstrictor agents
分类号 R575.2 [医药卫生—消化系统]
  • 相关文献

参考文献16

  • 1Salerno F, Gerbes A, Gin,s P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut, 2007, 56: 1310- 1318.
  • 2Moiler S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut, 2008, 57: 268-278.
  • 3Abraldes JG, Iwakiri Y, Loureiro-Silva M, et al. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest l.iver Physiol. 2006. 290: G980-987.
  • 4Krag A, Bendtsen F, Henriksen JH, et al. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and aseites. Gut, 2010, 59:105-110.
  • 5Soriano G, Castellote J, Alvarez C, et al. Secondary bacterial peritonitis in cirrhosis: a retrospective study of clinical and analytical characteristics, diagnosis and management. J Hepatol, 2010, 52: 39- 44.
  • 6Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology, 2008, 134:1360-1368.
  • 7Martin-Llahi M, P6pin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology, 2008, 134: 1352- 1359.
  • 8Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association.肝衰竭诊疗指南[J].中华肝脏病杂志,2006,14(9):643-646. 被引量：829
  • 9European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol, 2010, 53: 397-417.
  • 10Sharma P, Kumar A, Shrama BC, et al. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol, 2008, 103:1689-1697.

二级参考文献14

共引文献833

同被引文献18

  • 1Fernandez J,Arroyo VNovel definition of hepatorenal syndrome:clinical consequences. Front Gastrointest Res. Basel, Karger, 2011, 28: 122-129.
  • 2European Association for the Study of the Liver, Gines P, Angeli P, Lenz K,et al. EASL clinical practice guidelines on the management of asci- tes,spontaneous bacterial peritonitis, and hepatorenal syndrome in cir- rhosis. J Hepatol,2010,53:397-417.
  • 3Lenz K. Noradrenaline in the treatment of patients with hepatorenal syn- drome-back to the roots? J Hepatol,2012 ,57 :925-926.
  • 4Testro AG, Wongscelashote S, Angus PW, el al. Long-term outcome of patients treated with terlipressin fur types 1 and 2 hepatorenal syn- drome. J Gastroenterol Hepatol,2008 ,23 :1535-1540.
  • 5Nazar A, Pereira GH, Guevara M, et al. Predictors of response to therapy with terlipressin and albunfin in patients with cirrhosis and type 1 hepa- torenal syndrome. Hepatology,2010 ,51:219-226.
  • 6Sharma P, Kunmr A, Shrama BC, et al. An open label, pilot, randomized controlled trial of noradrenatine versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroen- tero1,2008,103 : 1689-1697.
  • 7Koda M, Murawaki Y, Kawasaki H. Renovaseular resistance assessed by color Doppler uhrasonography in patients with chronic liver diseases. J Gastroenterol Hepatol,2000,15 : 1424-1429.
  • 8Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology,2005 ,41:1211-1219.
  • 9Arroyo V, Gines P, Gerbes AL,et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis [ J ]. Hepatology, 1996,23 ( 1 ) : 164-176.
  • 10Salerno F, Gerbes A, Gin,s P, et al. Diagnosis, prevention and treat- ment of hepatorenal syndrome in cirrhosis [ J ]. Gut, 2007,56 ( 9 ) : 1310-1318.

引证文献2

二级引证文献4

中华肝脏病杂志
2011年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部